Global Digital Biomarkers Market

Focus on Key Trends, Growth Potential, Competitive Landscape, Components (Data Collection and Integration), End Users, Application (Sleep and Movement, Neuro, Respiratory and Cardiological Disorders) and Region – Analysis and Forecast, 2019-2025

Published Year: 2020
SKU: BH00814SA

8000

Online Access for One Person. Permission to Print

A quick peek into the report

Report Description

Market Report Coverage - Digital Biomarkers
Base Year : 2018
Market Size by 2018: $524.6 million

Market Report Coverage - Digital Biomarkers

Base Year

2018

Market Size by 2018

$524.6 million

Forecast Period

2019-2025

Value Projection and Estimation by 2025

$5,637.3 million

CAGR During Forecast Period

40.39%

Number of Tables

17

Number of Pages

433

Number of Figures

170

Research Hours

 270

 

 

Market Segmentation

• Application – Sleep and Movement, Cardiovascular, Mood and Behavior, Pain Management, Neurodegenerative Disorders, and Respiratory Conditions

• End Users – Biopharmaceutical Companies, Payers, and Providers
 

 

Regional Segmentation

• North America – U.S., Canada
• Europe –Netherlands, Germany, U.K., France, Spain, Italy, Russia
• Asia-Pacific – China, Japan, South Korea, India, Australia, Singapore
• Latin America- Brazil, Mexico

• Rest-of-the-World – Saudi Arabia, U.A.E., Israel, South Africa

Growth Drivers

• Increasing Cost of Drug Development

• Failure for Drugs for Neurodegenerative Disorder
• Regulatory Flexibility Toward Digital Health Solutions

• Explosion of Wearable Devices and Increasing Smartphone Penetration

Market Challenges

• Test and Validation
• Addressing Biases

• Validation Testing
• Integration

• Cost and Usability

Market Opportunities

• Personalized Medicine

• Investment in Voice-Based Digital Biomarkers

• Investment in Wearable Technology

Key Companies Profiled

ActiGraph LLC, Akili Interactive Labs, AliveCor Inc., Altoida Inc., Amgen Inc., Bayer AG, Biogen Inc., Eli Lilly and Company, Evidation Health Inc., Fitbit Inc., GlaxoSmithKline Plc., Human API, Happify Health, IXICO Plc., Neurotrack Technology Inc., Novartis, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi, Takeda Pharmaceuticals, Verily Life Science LLC.

 

Key Questions Answered:

What is the total addressable market (TAM) and the potential market opportunity for the global digital biomarkers market?

  • What is the total addressable market (TAM) and the potential market opportunity for the global digital biomarkers market?
  • What are the major market drivers and challenges of, and the opportunities in, the global digital biomarkers market?
  • What is the market share of the leading segments and sub-segments of the global digital biomarkers market in 2019 and 2025?
  • How did the global digital biomarkers market evolve?
  • How is each segment of the global digital biomarkers market expected to grow during the forecast period and what is the expected revenue to be generated by each of the segments by the end of 2025?
  • What are the consumer preferences in terms of adoption of wearable technology for the assessment of medical conditions?
  • What are the key development strategies implemented by the key players to stand out in this market?
  • What is the preferred business model used for building digital biomarkers?
  • Which area of application is expected to be the highest revenue generator in the global digital biomarkers market during the forecast period?
  • Which end-user segment is expected to be the highest revenue generator in this industry during the forecast period?
  • What is the potential of global digital biomarkers market in the emerging countries during the forecast period?

Market Overview

With the proliferation of digital tools such as smartphones and wearables globally, the rate at which health information

Market Overview

With the proliferation of digital tools such as smartphones and wearables globally, the rate at which health information is collected by these devices has significantly increased. The information collected also include digital biomarkers from patients.

The digital biomarker discovery is a great assistance for patients of chronic diseases. The chronic condition patients are neither able to have frequent consultations, nor can they recall their symptoms on a particular day. Thus, digital predictive biomarkers monitor the patient’s condition regularly and help in providing quality care.

Moreover, it is of immense benefit for a doctor to be able to measure and accurately track any subtle changes in the symptoms of a patient in order to prevent the progression of irreversible diseases such as Parkinson’s and Alzheimer’s. Hence, diagnostic biomarkers can be considered the future face of medicine and can help develop personalized treatments for patients.

Digital Biomarker

In 2018, the global digital biomarkers market was estimated to be $524.6 million and is expected to reach $5,637.3 million by the end of 2025, growing at a double-digit CAGR of 40.39% during the forecast period. The growth is primarily due to the increasing number of synergistic associations among the industry stakeholders.

This tremendous growth rate of the digital biomarkers market is facilitated by several factors, such as rapidly increasing uptake of smartphones, wearables, and the advent of high-speed networks and connectivity solutions. Currently, there are approximately 2.0 billion smartphone users globally, which is expected to reach nearly 6 billion in the coming years.

The use of high-speed networks, such as 3G and 4G, too, is set to increase by 73% by the end of 2020. Also, from a health perspective, there is an increasing demand for solutions which could efficiently minimize healthcare costs and help in the management of chronically ill patients by diagnosing ailments with different types of biomarkers.

In addition, the advent of connected digital platforms for detecting novel biomarkers such as wearable devices, biosensors, and portable devices have significantly enabled the accurate measurements of various physiological (such as sleep, activity, heart rate) as well as biochemical parameters (such as electrolytes, metabolites, small molecules, and proteins). This, in turn, provides enormous opportunities to revolutionize the data capture and collection process during clinical trials.

Competitive Landscape

The global digital biomarkers market is dominated by a plethora of digital health companies that can be categorized as developers of tools and sensors that collect patient-level data and developers of systems that integrate the collected patient data. Companies are continuously collaborating with research and medical institutions to expand the digital biomarker space.

In the three years (January 2016-September 2019), the market witnessed approximately 106 notable key developments. These included 34 synergistic activities, 46 product launches and enhancements, 22 business expansion and funding activities, and four acquisition, among others. Most of the companies are significantly undertaking synergistic activities to not only expand their global footprint but also to leverage technologies and products offered by other companies in a bid to consolidate the marketplace. Therefore, synergistic activities constitute the dominant contributor’s strategies.

Some of the major companies operating in the market, including ActiGraph, LLC., Akili Interactive Labs, AliveCor, Inc., Fitbit, Inc., HumanAPI, Novartis, Pfizer Inc. F. Hoffmann-La Roche Ltd, Sanofi, Takeda Pharmaceuticals, and Verily Life Science LLC.

Table of Contents

Executive Summary

Executive Summary

1    Product Definition

1    Product Definition
         1.1    Products Considered

2    Scope of the Report

2    Scope of the Report

3    Research Methodology

3    Research Methodology
         3.1    Global Digital Biomarkers Market: Research Methodology
                  3.1.1    Primary Data Sources
                  3.1.2    Secondary Data Sources

4    Digital Biomarkers: Global Perspective

4    Digital Biomarkers: Global Perspective
         4.1    Definition
         4.2    Current State of Digital Biomarkers
         4.3    Digital Biomarkers Ecosystem
                  4.3.1    Digital Platforms
                              4.3.1.1    Wearables Devices
                              4.3.1.2    Implantable Components/Sensors
                              4.3.1.3    Ingestible Sensors
                              4.3.1.4    Ocular Devices
                              4.3.1.5    Accelerometers
                              4.3.1.6    Smart Home Systems/IOTs
                              4.3.1.7    AR/VR Platforms
                              4.3.1.8    Desktop/Web Apps
         4.4    Data Measurements
                  4.4.1    Physiological Parameters
                  4.4.2    Behavioral Parameters
         4.5    Types of Biomarkers
                  4.5.1    Wellness
                  4.5.2    Disease
                  4.5.3    Drugs
         4.6    Industry
                  4.6.1    Pharmaceutical
                  4.6.2    Biotechnology/Life Sciences
                  4.6.3    Medical Devices
                  4.6.4    App Vendors
                  4.6.5    Clinical Trials (Clinical Research Organizations)
                  4.6.6    Technology Vendors
         4.7    Digital Biomarkers: Technology Landscape
                  4.7.1    Artificial Intelligence and Machine Learning
                  4.7.2    Augmented Reality and Virtual Reality
                  4.7.3    Blockchain
                  4.7.4    Edge Computing
                  4.7.5    Cloud Computing
         4.8    Successful Case Studies: Key Therapeutic Areas
                  4.8.1    Cardiovascular Disease
                  4.8.2    Parkinson’s Disease
                  4.8.3    Alzheimer’s Disease
                  4.8.4    Huntington's disease
 

5    Market Dynamics

5    Market Dynamics
         5.1    Growth Promoting Factors
                  5.1.1    Explosion of Wearable Devices and Increasing Smartphone Penetration
                  5.1.2    Increasing Cost of Drug Development
                  5.1.3    Failure of Drugs for Neurodegenerative Disorder
                  5.1.4    Regulatory Flexibility Toward Digital Health Solutions
         5.2    Market Challenges
                  5.2.1    Need for Standardized and Interoperable Solutions
                  5.2.2    Difference or Inaccuracy in Data Measurements
                  5.2.3    Lack of Integration and Interoperability Between Medical Records and User Generated Data
                  5.2.4    Lack of Use Cases Pertaining to the Return on Investment (ROI) Analysis
         5.3    Market Opportunities
                  5.3.1    Digital Biomarkers: The Future of Precision Medicine
                  5.3.2    Investment in Voice-Based Digital Biomarkers
                  5.3.3    Investment in Wearable Technology
                              5.3.3.1    Early Detection of Neurological Disorders
                              5.3.3.2    For General Health Management
                              5.3.3.3    Metabolic, Cardiovascular, and Gastrointestinal Health
                              5.3.3.4    Maternal, Pre- and Neo-Natal Care
                              5.3.3.5    Pulmonary Health and Environmental Exposures
 

 6    Competitive Landscape

 6    Competitive Landscape
         6.1    Key Strategies and Developments
                  6.1.1    Synergistic Interactions
                  6.1.2    Product Launches and Enhancements
                  6.1.3    Business Expansion and Funding Activities
                  6.1.4    Acquisitions, Approvals, and Others

7    Digital Biomarker Market Opportunities and Growth,  2018-2025 ($Million)

7    Digital Biomarker Market Opportunities and Growth,  2018-2025 ($Million)
         7.1    Data Collection (Sensors and Tools that Collect Data)
                  7.1.1    Wearables Devices
                              7.1.1.1    Evolution of Wearable Devices in Clinical Trials
                              7.1.1.2    Wearable Devices in Clinical Trials
                              7.1.1.3    Actigraphy Devices
                                             7.1.1.3.1    Generational Change from Polysomnography to Actigraphy
                                             7.1.1.3.2    ActiGraph
                              7.1.1.4    Market Estimation and Forecast, 2018-2025
                              7.1.1.5    Opportunity in Digital Biomarker
                              7.1.1.6    New Developments
         7.2    Implantable/Ingestible Biosensors
                  7.2.1    Market Estimation and Forecast, 2018-2025
                  7.2.2    Opportunity in Digital Biomarker
         7.3    Mobile/Tablet Apps
                  7.3.1    Market Estimation and Forecast, 2018-2025
                  7.3.2    Opportunity in Digital Biomarker
                  7.3.3    New Developments
                  7.3.4    Competitive Landscape
         7.4    Data Integration
                  7.4.1    Market Estimation and Forecast, 2018-2025
                  7.4.2    Competitive Landscape
         7.5    Global Digital biomarkers Market (by Application)
                  7.5.1    Gastrointestinal Diseases
                              7.5.1.1    Inflammatory Bowel’s Disease
                  7.5.2    Sleep and Movement
                  7.5.3    Cardiovascular
                  7.5.4    Mood and Behavior (Psychiatric Disorders)
                  7.5.5    Chronic Pain
                  7.5.6    Neurodegenerative Disorders
                              7.5.6.1    Parkinson’s Disease
                              7.5.6.2    Multiple Sclerosis
                              7.5.6.3    Alzheimer’s Disease
                  7.5.7    Diabetes
                  7.5.8    Respiratory Conditions
                  7.5.9    Others

 8    Global Digital Biomarkers Market, by End Users

 8    Global Digital Biomarkers Market, by End Users
         8.1    Biopharmaceutical Companies
                  8.1.1    Role of Biopharma Companies in the Development of Digital Biomarkers
                  8.1.2    Major Therapeutic Areas for Biomarkers
                              8.1.2.1    Respiratory Diseases
                              8.1.2.2    Neurodegenerative Diseases
                              8.1.2.3    Cardiovascular Diseases
                              8.1.2.4    Diabetes
         8.2    Payers
         8.3    Providers

9    Global Digital Biomarkers Market (by Region)

9    Global Digital Biomarkers Market (by Region)
         9.1    North America
                  9.1.1    U.S
                              9.1.1.1    Digital Health Scenario
                              9.1.1.2    Degree of Adoption of Wearables
                              9.1.1.3    Degree of Adoption of Mobile Health Applications
                              9.1.1.4    Local Players in the Digital Biomarker Market
                              9.1.1.5    Regulatory Scenario
                  9.1.2    Canada
                              9.1.2.1    Digital Health Scenario
                              9.1.2.2    Degree of Adoption of Wearables
                              9.1.2.3    Degree of Adoption of Mobile Health Applications Adoption
                              9.1.2.4    Local Digital Biomarker Market
                              9.1.2.5    Regulatory Scenario
                              9.1.2.6    Future of Digital Health in Canada
         9.2    Europe
                  9.2.1    Netherlands
                              9.2.1.1    Digital Health Scenario
                              9.2.1.2    Level of Wearables Adoption
                              9.2.1.3    Degree of Adoption of Mobile Health Applications
                              9.2.1.4    Local Players in the Digital Biomarker Market
                  9.2.2    Germany
                              9.2.2.1    Digital Health Scenario
                              9.2.2.2    Degree of Adoption of Wearables
                              9.2.2.3    Reluctance to Fitness Trackers
                              9.2.2.4    Future of Digital Health in Germany
                  9.2.3    U.K.
                              9.2.3.1    Digital Health Scenario
                              9.2.3.2    Degree of Adoption of Wearables
                              9.2.3.3    Increasing Sales of Smartwatches
                              9.2.3.4    Abandonment of Wearables
                              9.2.3.5    Local Players in Wearables
                  9.2.4    France
                              9.2.4.1    Digital Health Scenario
                              9.2.4.2    Degree of Wearables Adoption
                              9.2.4.3    Local Players in Digital Biomarkers Market
                  9.2.5    Spain
                              9.2.5.1    Digital Health Scenario
                              9.2.5.2    Degree of Adoption of Wearables
                  9.2.6    Italy
                              9.2.6.1    Digital Health Scenario
                              9.2.6.2    Degree of Adoption of Wearables
                              9.2.6.3    Degree of Adoption of Mobile Health Applications
                  9.2.7    Russia
                              9.2.7.1    Digital Health Scenario
                              9.2.7.2    Degree of Adoption of Wearables
                              9.2.7.3    Degree of Adoption of Mobile Health Applications
                  9.2.8    Rest-of-Europe
                              9.2.8.1    Digital Health Scenario
                              9.2.8.2    Degree of Adoption of Wearables
                              9.2.8.3    Degree of Adoption of Mobile Health Applications
                              9.2.8.4    Local Player in Digital Biomarker Market
         9.3    Asia-Pacific
                  9.3.1    China
                              9.3.1.1    Digital Health Scenario
                              9.3.1.2    Degree of Adoption of Wearables
                              9.3.1.3    Degree of Adoption of Mobile Health Applications
                              9.3.1.4    Local Players in Digital Biomarker Market
                 9.3.2    Japan
                              9.3.2.1    Digital Health Scenario
                              9.3.2.2    Degree of Wearables Adoption
                              9.3.2.3    Degree of Mobile Health Applications Adoption
                              9.3.2.4    Local Players in Digital Biomarker Market
                 9.3.3    South Korea
                              9.3.3.1    Digital Health Scenario
                              9.3.3.2    Degree of Adoption of Wearables
                              9.3.3.3    Degree of Adoption of Mobile Health Applications
                  9.3.4    India
                              9.3.4.1    Digital Health Scenario
                              9.3.4.2    Degree of Adoption of Wearables
                              9.3.4.3    Degree of adoption of Mobile Health Applications
                              9.3.4.4    Local Players in Digital Biomarker Market
                  9.3.5    Australia
                              9.3.5.1    Digital Health Scenario
                              9.3.5.2    Level of Wearables Adoption
                              9.3.5.3    Level of Mobile Health Applications Adoption
                  9.3.6    Singapore
                              9.3.6.1    Digital Health Scenario
                              9.3.6.2    Degree of Adoption of Wearables
                              9.3.6.3    Degree of Adoption of Mobile Health Applications
                  9.3.7    Rest-of-Asia-Pacific
                              9.3.7.1    Digital Health Scenario
                              9.3.7.2    Degree of adoption of Wearables and Mobile Health Application
         9.4    Latin America
                  9.4.1    Brazil
                              9.4.1.1    Digital Health Scenario
                              9.4.1.2    Degree of Adoption of Wearables
                              9.4.1.3    Degree of Adoption of Mobile Health Applications
                  9.4.2    Mexico
                              9.4.2.1    Digital Health Scenario
                              9.4.2.2    Degree of Adoption of Wearables
                              9.4.2.3    Degree of Adoption of Mobile Health Applications
         9.5    Rest-of-the-World
                  9.5.1    Saudi Arabia
                              9.5.1.1    Digital Health Scenario
                              9.5.1.2    Degree of Adoption of Wearables
                              9.5.1.3    Degree of Adoption of Mobile Health Applications
                  9.5.2    U.A.E.
                              9.5.2.1    Digital Health Scenario
                              9.5.2.2    Degree of Adoption of Wearables and Mobile Health Applications
                  9.5.3    Israel
                              9.5.3.1    Digital Health Scenario
                              9.5.3.2    Degree of Adoption of Wearables
                  9.5.4    South Africa
                              9.5.4.1    Digital Health Scenario
                              9.5.4.2    Degree of Adoption of Wearables
                              9.5.4.3    Degree of Adoption of Mobile Health Applications
 

10    Company Profiles

 10    Company Profiles
           10.1    Overview
           10.2    ActiGraph, LLC
                      10.2.1    Company Overview
                      10.2.2    Role of ActiGraph, LLC in the Global Digital Biomarkers Market
                      10.2.3    Recent Developments
                      10.2.4    SWOT Analysis: ActiGraph, LLC
           10.3    Akili Interactive Labs
                      10.3.1    Company Overview
                      10.3.2    Role of Akili Interactive Labs in the Global Digital Biomarkers Market
                      10.3.3    Recent Developments
                      10.3.4    SWOT Analysis
           10.4    AliveCor Inc.
                      10.4.1    Company Overview
                      10.4.2    Role of AliveCor, Inc. in the Global Digital Biomarkers Market
                      10.4.3    Recent Development
                      10.4.4    SWOT Analysis
           10.5    Altoida AG
                      10.5.1    Company Overview
                      10.5.2    Role of Altoida AG in the Global Digital Biomarkers Market
                      10.5.3    Recent Developments
                      10.5.4    SWOT Analysis
           10.6    Amgen Inc
                      10.6.1    Company Overview
                      10.6.2    Role of Amgen Inc. in the Global Digital Biomarkers Market.
                      10.6.3    Financials
                      10.6.4    Key Insights About Financial Health of the Company
                      10.6.5    Recent Developments
                      10.6.6    SWOT Analysis
           10.7    Bayer AG
                      10.7.1    Company Overview
                      10.7.2    Role of Bayer AG in the Global Digital Biomarkers Market
                      10.7.3    Financials
                      10.7.4    Key Insights About Financial Health of the Company
                      10.7.5    Recent Developments
                      10.7.6    SWOT Analysis
           10.8    Biogen Inc.
                      10.8.1    Company Overview
                      10.8.2    Role of Biogen Inc. in the Global Digital Biomarkers Market
                      10.8.3    Financials
                      10.8.4    Key Insights About Financial Health of the Company
                      10.8.5    Recent Developments
                      10.8.6    SWOT Analysis
           10.9    Eli Lilly and Company
                      10.9.1    Company Overview
                      10.9.2    Role of Eli Lilly and Company in the Global Digital Biomarkers Market
                      10.9.3    Financials
                      10.9.4    Key Insights About Financial Health of the Company
                      10.9.5    Recent Developments
                      10.9.6    SWOT Analysis
          10.10   Evidation Health, Inc.
                      10.10.1    Company Overview
                      10.10.2    Role of Evidation Health, Inc. in the Global Digital Biomarker Market
                      10.10.3    Recent Developments
                      10.10.4    SWOT Analysis
          10.11   F. Hoffmann-La Roche Ltd
                      10.11.1    Company Overview
                      10.11.2    Role of F. Hoffmann-La Roche Ltd in the Global Digital Biomarkers Market
                      10.11.3    Financials
                      10.11.4    Key Insights About Financial Health of the Company
                      10.11.5    Recent Developments
                      10.11.6    SWOT Analysis
          10.12   Fitbit, Inc.
                      10.12.1    Company Overview
                      10.12.2    Role of Fitbit Inc. in the Global Digital Biomarker Market
                      10.12.3    Financials
                      10.12.4    Key Insights About Financial Health of the Company
                      10.12.5    Recent Developments
                      10.12.6    SWOT Analysis
          10.13   GlaxoSmithKline Plc
                      10.13.1    Company Overview
                      10.13.2    Role of GlaxoSmithKline Plc in the Global Digital Biomarkers Market
                      10.13.3    Financials
                      10.13.4    Key Insights About Financial Health of the Company
                      10.13.5    Recent Developments
                      10.13.6    SWOT Analysis
          10.14   Human API
                      10.14.1    Company Overview
                      10.14.2    Role of Human API in the Global Digital Biomarkers Market
                      10.14.3    Recent Developments
                      10.14.4    SWOT Analysis
          10.15   Happify Health
                      10.15.1    Company Overview
                      10.15.2    Role of Happify Health in the Global Digital Biomarker Market
                      10.15.3    Recent Developments
                      10.15.4    SWOT Analysis
          10.16   IXICO Plc
                      10.16.1    Company Overview
                      10.16.2    Role of IXICO Plc in the Global Digital Biomarkers Market
                      10.16.3    Financials
                      10.16.4    Key Insights About Financial Health of the Company
                      10.16.5    Recent Developments
                      10.16.6    SWOT Analysis
          10.17   Koninklijke Philips N.V.
                      10.17.1    Company Overview
                      10.17.2    Role of Koninklijke Philips N.V. in the Global Digital Biomarkers Market
                      10.17.3    Financials
                      10.17.4    Key Insights About Financial Health of the Company
                      10.17.5    Recent Developments
                      10.17.6    SWOT Analysis
          10.18   Medopad Ltd
                      10.18.1    Company Overview
                      10.18.2    Role of Medopad Ltd in the Global Digital Biomarker Market
                      10.18.3    Recent Developments
                      10.18.4    SWOT Analysis
          10.19   Mindstrong Health
                      10.19.1    Company Overview
                      10.19.2    Role of Mindstrong Health in the Global Digital Biomarker Market
                      10.19.3    Recent Developments
                      10.19.4    SWOT Analysis
          10.20   Neurotrack Technologies, Inc.
                      10.20.1    Company Overview
                      10.20.2    Role of Neurotrack Technologies, Inc in the Global Digital Biomarker Market
                      10.20.3    Recent Developments
                      10.20.4    SWOT Analysis
          10.21   Novartis International AG
                      10.21.1    Company Overview
                      10.21.2    Role of Novartis International AG in the Global Digital Biomarkers Market
                      10.21.3    Financials
                      10.21.4    Key Insights About Financial Health of the Company
                      10.21.5    Recent Developments
                      10.21.6    SWOT Analysis
          10.22   Orikami
                      10.22.1    Company Overview
                      10.22.2    Role of Orikami in the Global Digital Biomarker Market
                      10.22.3    Recent Developments
                      10.22.4    SWOT Analysis
          10.23   Pfizer Inc.
                      10.23.1    Company Overview
                      10.23.2    Role of Pfizer Inc in the Global Digital Biomarkers Market
                      10.23.3    Financials
                      10.23.4    Key Insights About Financial Health of the Company
                      10.23.5    Recent Developments
                      10.23.6    SWOT Analysis
          10.24   Quanterix Corporation
                      10.24.1    Company Overview
                      10.24.2    Role of Quanterix Corporation in the Global Digital Biomarker Market
                      10.24.3    Financials
                      10.24.4    Key Insights About Financial Health of the Company
                      10.24.5    Recent Developments
                      10.24.6    SWOT Analysis
          10.25   Sanofi S.A.
                      10.25.1    Company Overview
                      10.25.2    Role of Sanofi S.A. in the Global Digital Biomarker Market
                      10.25.3    Financials
                      10.25.4    Key Insights About Financial Health of the Company
                      10.25.5    Recent Developments
                      10.25.6    SWOT Analysis
           10.26   The Takeda Pharmaceuticals Company Limited
                      10.26.1    Company Overview
                      10.26.2    Role of The Takeda Pharmaceuticals Company Limited in the Global Digital Biomarkers Market
                      10.26.3    Financials
                      10.26.4    Key Insights About Financial Health of the Company
                      10.26.5    Recent Developments
                      10.26.6    SWOT Analysis
          10.27   Verily Life Sciences
                      10.27.1    Company Overview
                      10.27.2    Role of Verily Life Sciences in the Global Digital Biomarkers Market
                      10.27.3    Recent Developments
                      10.27.4    SWOT Analysis: Verily Life Sciences
          Company Snapshots
          10.28   Cambridge Cognition Plc
                      10.28.1    Company Overview
                      10.28.2    Role of Cambridge Cognition Plc. in the Global Digital Biomarkers Market
                      10.28.3    Recent Developments
          10.29   MC10 Inc.
                      10.29.1    Company Overview
                      10.29.2    Role of MC10 Inc. in the Global Digital Biomarkers Market
                      10.29.3    Recent Developments
          10.30   Medical Care Corporation
                      10.30.1    Company Overview
                      10.30.2    Role of Medical Care Corporation in the Global Digital Biomarkers Market
          10.31   Shimmer
                      10.31.1    Company Overview
                      10.31.2    Role of Shimmer in the Global Digital Biomarkers Market
                      10.31.3    Recent Developments
          10.32   Winterlight Labs Inc.
                      10.32.1    Company Overview
                      10.32.2    Role of Winterlight Labs, Inc. in the Global Digital Biomarkers Market
                      10.32.3    Recent Developments

List of Tables

List of Tables

Table 1:    A Comparison Between Examples of Clinical Biomarkers and Digital Biomarkers
Table 2:    Percentage of Different Wearable Technology Brands Being Used in Clinical Trials (As of December 2019, N=1600)
Table 3:    Regional Perspective: From Consumer (Non-Clinical) Generated Data, $Million, 2018-2025
Table 4:    Regional Perspective: Patient Centric Data During Clinical Trials, $Million, 2018-2025
Table 4.1:    Different Categories of Mobile Health Applications
Table 5.1:    Leading Wearable Devices and Their Features
Table 5.2:    Major FDA Clearances in 2019
Table 6.1:    Synergistic Activities Share (by Company), January 2016– September 2019
Table 6.2:    Product Launches and Enhancements Share (by Company), January 2016 – September 2019
Table 6.3:    Business Expansion and Funding Activities Share (by Company), January 2016 – September 2019
Table 6.4:    Key Acquisitions in the global digital biomarkers Space (2019)
Table 7.4:    Distribution of Clinical Trials Performed Using Wearable Connected Devices (Up to Dec 2019)
Table 7.5:    ActiGraph Objective Measures
Table 7.6:    Recent Key Developments in the Digital Biomarker Space in Terms of Wearable Devices
Table 7.7:    Some of the recent developments in this segment
Table 7.9:    Potential Digital Tools for the Measurement of Outcomes for Inflammatory Bowel’s Disease
Table 7.10:    Overview of Clinical Trials Performed Using Mobile Application for the Monitoring/Management of IBD
Table 7.11:    Commercially Available Mobile Apps Used for the Monitoring and Management of Inflammatory Bowel’s Disease
Table 7.14:    Clinical Trials Using Mobile Application for the Assessment of Sleep-Related Disorders:
Table 7.15:    Clinical Trials Using Wearable Devices for the Assessment of Sleep-Related Disorders
Table 7.16:    Some of the key developments in the Field of Sleep Disorders Using Digital Health
Table 7.17:    Overview of Clinical Trials Performed Using Mobile Application for the Monitoring/Management of Cardiovascular Diseases
Table 7.18:    Overview of Clinical Trials Performed Using Wearable Devices for the Monitoring/Management of Cardiovascular Diseases
Table 7.19:    Recent Developments Using Wearable Developments for the Assessment of Cardiovascular Diseases
Table 7.20:    Clinical Trials Using Actigraphy devices for the Assessment of Mood Disorders
Table 7.22:    Recent Developments in the Mood Related Disorders Space
Table 7.23:    Number of Clinical Trials Using a Mobile Application, 2019
Table 7.24:    Increased Use of Wearable Devices in Clinical Trials for Chronic Pain
Table 7.25:    Recent Key Developments in the Field of Digital Tech Assisted Chronic Pain Management
Table 7.26:    Top 5 Clinical Trials on Parkinson’s Disease Conducted Using Smartphone Apps
Table 7.27:    Some of the Clinical Trials on Parkinson’s Disease Conducted Using Wearable Devices
Table 7.28:    Top 5 Clinical Trials on Multiple Sclerosis Conducted Using Smartphone Apps
Table 7.29:    Some of The Clinical Trials on Multiple Sclerosis Conducted Using Wearable Devices
Table 7.30:    Top 5 Clinical Trials on Alzheimer’s Disease Conducted Using Smartphone Apps
Table 7.31:    Some of the Clinical Trials on Alzheimer’s Disease Conducted Using Wearable Devices
Table 7.32:    Recent Developments in the Neurodegenerative Disease Space Pertaining to Digital Biomarkers
Table 7.33:    Clinical Trials Using Mobile Application for the Management of Diabetes:
Table 7.34:    Clinical Trials Using Wearable Devices to Manage Diabetes
Table 7.35:    Key Developments Involving Wearables/Mobile Application in the Management of Diabetes
Table 7.36:    Leading Respiratory Conditions and Related Deaths
Table 7.37:    Top 5 Clinical Trials on Respiratory Disease Conducted Using Mobile Apps
Table 7.38:    Some of the Clinical Trials on Respiratory Disease Conducted Using Wearable Devices
Table 7.39:    Recent Developments in the Respiratory Segment
Table 9.1:    Different Types of Health Tracking People and Their Characteristics
Table 9.4:    Rate of Usage of Wearables in Italy
Table 9.5:    Different Classes of Mobile Application in Healthcare and their Rate of Usage (%)
Table 9.6:    Different European Countries and the Level of Adoption of Consumer Wearables (in Percentage, 2019)
Table 9.7:    Different Wearables and Their Adoption Rates in Australia
Table 9.8:    Different Wearables and Their Expected Adoption Rates in Australia
Table 9.9:    Different Wearables and Their Adoption Rates in Singapore
Table 9.10:    Different Wearables and Their Expected Adoption Rates in Singapore
Table 9.11:    Different Wearables and Their Adoption Rates in Mexico
Table 9.12:    Different Wearables and Their Expected Adoption Rates in Singapore
Table 10.1:    Clinical Trials Involving Devices from ActiGraph, LLC
Table 10.2:    Akili Interactive Labs: Clinical Trials
Table 10.3:    AliveCor, Inc.: Clinical Trials
Table 10.4:    Altoida AG: Clinical Trials
Table 10.5:    Bayer AG: Clinical Trial
Table 10.6:    Biogen Inc.: Clinical Trial
Table 10.7:    Eli Lilly and Company: Clinical Trials
Table 10.8:    Evidation Health, Inc.: Clinical Trials
Table 10.9:    F. Hoffmann-La Roche Ltd: Clinical Trials
Table 10.10:    Fitbit, Inc.: Clinical Trials
Table 10.11:    GlaxoSmithKline Plc: Clinical Trials
Table 10.12:    Happify Health: Clinical Trials
Table 10.13:    Koninklijke Philips N.V.
Table 10.14:    Medopad Ltd: Clinical Trials
Table 10.15:    Mindstrong Health: Clinical Trials
Table 10.16:    Neurotrack Technologies, Inc.: Clinical Trials
Table 10.17:    Novartis International AG: Clinical Trials
Table 10.18:    Pfizer Inc:  Clinical Trials
Table 10.19:    Quanterix Corporation: Clinical Trials
Table 10.20:    Verily Life Sciences: Projects
Table 10.21:    Verily Life Sciences: Clinical Trials
Table 10.22:    MC10 Inc: Clinical Trials
Table 10.23:    Shimmer: Clinical Trials
Table 10.24:    Winterlight Labs, Inc: Clinical Trials
 

List of Figures

List of Figures

Figure 1:    Global Subscriber Base and Smartphone Penetration
Figure 2:    Number of Clinical Trials Using Connected Wearable Devices by Year (Cumulative)
Figure 3:    Percentage of Completed and Active Clinical Trials Using Wearables (As of December 2019, N=1600)
Figure 5:    Global Digital Biomarkers Market (by Type), $Million, 2018-2025
Figure 6:    Global Digital Biomarkers Market, Provider Type (Data Collection), $Million, 2018-2025
Figure 7:    Global Digital Biomarkers Market, Data Collection System Type, $Million, 2018-2025
Figure 8:    Global Digital Biomarkers Market, Data Integration System Providers, $Million, 2018-2025
Figure 9:    Global Digital Biomarkers Market (Application/Therapeutic Area), $Million, 2018-2025
Figure 10:    Share of Leading Therapeutic Areas in the Digital Biomarkers Market, 2018 and 2025 (Market Size: 2018 = $524.6 million, 2025 = $5.63 billion)
Figure 11:    Global Digital Biomarkers Market (End Users), $Million, 2018-2025
Figure 12:    Current Penetration of Different End User Groups in the Digital Biomarkers  Market (2018)
Figure 2.1:    Global Digital Biomarkers Market: Breakup of the Market
Figure 3.1:    Global Digital Biomarkers Market Research Methodology
Figure 3.2:    Primary Research
Figure 3.3:    Secondary Research
Figure 3.4:    Data Triangulation
Figure 3.5:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.6:    Top-Down Approach (Segment-Wise Analysis)
Figure 3.7:    Assumptions and Limitations
Figure 3.8:    Considered Factors for Data Prediction and Modeling
Figure 3.9:    Scope Definition for the Global Digital Biomarkers Market
Figure 4.1:    Major Components of Digital Biomarkers Market
Figure 4.2:    A Flowchart Depicting the Conversion of Healthcare Data to a Digital Biomarker
Figure 4.3:    Different Populations of Data Producers of Digital Biomarkers
Figure 5.1:    Number of Alzheimer's Disease Drug Under Development
Figure 6.1:    Share of Key Developments and Strategies, January 2016–September 2019 (Total Developments = 106)
Figure 7.1:    Global Digital Biomarker Data Collection Market ($million), 2018-2025
Figure 7.2:    Wearable Devices and its Market Share (in Units) in Global Healthcare Sector
Figure 7.3:    Clinical Trials Using Connected Wearable Devices by Year (Cumulative)
Table 7.1:    Number of Clinical Trials Performed Using Different Brands of Wearables Catering to Diverse Therapeutic Areas (Cumulative, As of 2019)
Table 7.2:    Distribution of Number of Clinical Trials Using Wearable Devices, by Country (Up to Dec 2019)
Table 7.3:    A Comparative Analysis on the Commercially Available Actigraphy Devices
Figure 7.4:    Distribution of Number of Clinical Trials Using Actigraphy Devices, by Region (Cumulative as of 2019)
Figure 7.5:    Distribution of Number of Clinical Trials Using ActiGraph Devices, by Therapeutic Areas (Cumulative as of 2019)
Figure 7.6:    Evolution of Four Generations of ActiGraph Activity Monitors
Figure 7.7:    Global Wearable Devices Digital Biomarkers Market ($million), 2018-2025
Figure 7.8:    Global Implantable Components/Biosensors Market, $Million, 2018-2025
Figure 7.9:    Global Mobile/Tablet Apps Market, $Million, 2018-2025
Figure 7.10:    Global Data Integration Systems Market, $Million, 2018-2025
Figure 7.11:    Global Digital Biomarkers Market, Application Type: Gastrointestinal Diseases, $Million, 2018-2025
Figure 7.12:    Global Digital Biomarkers Market, Application Type: Sleep Disorders, $Million, 2018-2025
Figure 7.13:    Global Digital Biomarkers Market, Application Type: Cardiovascular, $Million, 2018-2025
Figure 7.14:    Global Digital Biomarkers Market, Application Type: Mood and Behavior, $Million, 2018-2025
Figure 7.15:    Global Digital Biomarkers Market, Application Type: Chronic Pain, $Million, 2018-2025
Figure 7.16:    Global Digital Biomarkers Market, Application Type: Neurodegenerative Disorders, $Million, 2018-2025
Figure 7.17:    Global Digital Biomarkers Market, Application Type: Respiratory Conditions, $Million, 2018-2025
Figure 7.18:    Global Digital Biomarkers Market, Application Type: Respiratory Conditions, $Million, 2018-2025
Figure 7.19:    Global Digital Biomarkers Market, Application Type: Other Therapeutic Areas, $Million, 2018-2025
Figure 8.1:    Potential Use Cases of Digital Biomarkers (From an End User Perspective)
Figure 8.2:    Global Digital Biomarkers Market, End User Type: Biopharma companies, $Million, 2018-2025
Figure 8.3:    Global Digital Biomarkers Market, End User Type: Health Insurance Payers, $Million, 2018-2025
Figure 8.4:    Global Digital Biomarkers Market, End User Type: Healthcare Providers, $Million, 2018-2025
Figure 9.1:    North America Digital Biomarkers Market, Clinical Trials, $Million, 2018-2025
Figure 9.2:    North America Digital Biomarkers Market, Non-Clinical, $Million, 2018-2025
Figure 9.3:    Factors Influencing Digital Biomarkers Market in North America
Figure 9.4:    U.S. Digital Biomarkers Market, $Million, 2018-2025
Figure 9.5:    U.S. Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.6:    Canada Digital Biomarkers Market, $Million, 2018-2025
Figure 9.7:    Canada Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.8:    Mobile Health Applications: Usage Areas (As of 2019)
Figure 9.9:    Europe Digital Biomarkers Market, $Million, 2018-2025
Figure 9.10:    Factors Influencing Digital Biomarkers Market in Europe
Figure 9.11:    Netherlands Digital Biomarkers Market, $Million, 2018-2025
Figure 9.12:    Netherlands Digital Biomarkers Market, by Settings, $Million, 2018-2025
Figure 9.13:    Germany Digital Biomarkers Market, $Million, 2018-2025
Figure 9.14:    Germany Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.15:    U.K. Digital Biomarkers Market, $Million, 2018-2025
Figure 9.16:    U.K. Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.17:    France Digital Biomarkers Market, $Million, 2018-2025
Figure 9.18:    France Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.19:    Spain Digital Biomarkers Market, $Million, 2018-2025
Figure 9.20:    Spain Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.21:    Italy Digital Biomarkers Market, $Million, 2018-2025
Figure 9.22:    Italy Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.23:    Russia Digital Biomarkers Market, $Million, 2018-2025
Figure 9.24:    Russia Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.25:    Belgium Digital Biomarkers Market, $Million, 2018-2025
Figure 9.26:    Sweden Digital Biomarkers Market, $Million, 2018-2025
Figure 9.27:    Denmark Digital Biomarkers Market, $Million, 2018-2025
Figure 9.28:    Norway Digital Biomarkers Market, $Million, 2018-2025
Figure 9.29:    Asia-Pacific Digital Biomarkers Market, $Million, 2018-2025
Figure 9.30:    Factors Influencing Digital Biomarkers Market in Asia-Pacific
Figure 9.31:    China Digital Biomarkers Market, $Million, 2018-2025
Figure 9.32:    China Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.33:    Japan Digital Biomarkers Market, $Million, 2018-2025
Figure 9.34:    Japan Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.35:    South Korea Digital Biomarkers Market, $Million, 2018-2025
Figure 9.36:    South Korea Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.37:    India Digital Biomarkers Market, $Million, 2018-2025
Figure 9.38:    India Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.39:    Australia Digital Biomarkers Market, $Million, 2018-2025
Figure 9.40:    Australia Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.41:    Singapore Digital Biomarkers Market, $Million, 2018-2025
Figure 9.42:    Latin America Digital Biomarkers Market, $Million, 2018-2025
Figure 9.43:    Factors Influencing Digital Biomarkers Market in Latin America
Figure 9.44:    Brazil Digital Biomarkers Market, $Million, 2018-2025
Figure 9.45:    Brazil Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.46:    Mexico Digital Biomarkers Market, $Million, 2018-2025
Figure 9.47:    Mexico Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.48:    Rest-of-the-World Digital Biomarkers Market, $Million, 2018-2025
Figure 9.49:    Factors Influencing Digital Biomarkers Market in Rest-of-the-World
Figure 9.50:    Saudi Arabia Digital Biomarkers Market, $Million, 2018-2025
Figure 9.51:    Saudi Arabia Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.52:    U.A.E. Digital Biomarkers Market, $Million, 2018-2025
Figure 9.53:    U.A.E. Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.54:    Israel Digital Biomarkers Market, $Million, 2018-2025
Figure 9.55:    Israel Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 9.56:    South Africa Digital Biomarkers Market, $Million, 2018-2025
Figure 9.57:    South Africa Digital Biomarkers Market (by Setting), $Million, 2018-2025
Figure 10.1:    Total Number of Companies Profiled
Figure 10.2:    ActiGraph, LLC: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.3:    ActiGraph, LLC.: SWOT Analysis
Figure 10.4:    Akili Interactive Labs: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.5:    Akili Interactive Labs: SWOT Analysis
Figure 10.6:    AliveCor, Inc: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.7:    AliveCor Inc.: SWOT Analysis
Figure 10.8:    Altoida, AG: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.9:    Altoida AG.: SWOT Analysis
Figure 10.10:    Amgen Inc: Overall Financials, 2016-2018
Figure 10.11:    Amgen Inc. Revenue (by Region), 2016-2018
Figure 10.12:    Amgen Inc.  R&D Expenditure, 2016-2018
Figure 10.13:    Amgen Inc: SWOT Analysis
Figure 10.14:    Bayer AG.: Overall Financials, 2016-2018
Figure 10.15:    Bayer AG: Revenue (by Segment), 2016-2018
Figure 10.16:    Bayer Inc: Revenue (by Region), 2016-2018
Figure 10.17:    Bayer AG: R&D Expenditure, 2016-2018
Figure 10.18:    Bayer AG: SWOT Analysis
Figure 10.19:    Biogen Inc: Overall Financials, 2016-2018
Figure 10.20:    Biogen Inc.: Revenue (by Region), 2016-2018
Figure 10.21:    Biogen Inc.: R&D Expenditure, 2016-2018
Figure 10.22:    Biogen Inc: SWOT Analysis
Figure 10.23:    Eli Lilly and Company: Overall Financials, 2016-2018
Figure 10.24:    Eli Lilly and Company: Revenue (by Segment), 2016-2018
Figure 10.25:    Eli Lilly and Company: Revenue (by Region), 2016-2018
Figure 10.26:    Eli Lilly and Company: R&D Expenditure, 2016-2018
Figure 10.27:    Eli Lilly and Company: SWOT Analysis
Figure 10.28:    Evidation Health, Inc.: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.29:    Evidation Health, Inc: SWOT Analysis
Figure 10.30:    F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 10.31:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 10.32:    F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 10.33:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 10.34:    F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 10.35:    Fitbit, Inc: Product Portfolio for Global Digital Biomarkers Market
Figure 10.36:    Fitbit Inc.: Overall Financials, 2016-2018
Figure 10.37:    Fitbit Inc.: Revenue (by Region), 2016-2018
Figure 10.38:    Fitbit, Inc.: R&D Expenditure, 2016-2018
Figure 10.39:    Fitbit Inc.: SWOT Analysis
Figure 10.40:    GlaxoSmithKline Plc: Overall Financials, 2016-2018
Figure 10.41:    GlaxoSmithKline Plc: Revenue (by Business Segments), 2016-2018
Figure 10.42:    GlaxoSmithKline: Revenue (by Region), 2016-2018
Figure 10.43:    GlaxoSmithKline Plc: R&D Expenditure, 2016-2018
Figure 10.44:    GlaxoSmithKlin Plc SWOT Analysis
Figure 10.45:    Human API: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.46:    Human API: SWOT Analysis
Figure 10.47:    Happify Health: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.48:    Happify: SWOT Analysis
Figure 10.49:    IXICO Plc: Product Portfolio for Global Digital Biomarkers Market
Figure 10.50:    IXICO plc: Overall Financials, 2016-2018
Figure 10.51:    IXICO plc: Revenue (by Region), 2016-2018
Figure 10.52:    IXICO plc: R&D Expenditure, 2016-2018
Figure 10.53:    IXICO plc: SWOT Analysis
Figure 10.54:    Koninklijke Philips N.V.: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.55:    Koninklijke Philips N.V.: Overall Financials ,2016-2018
Figure 10.56:    Koninklijke Philips N.V.: Revenue (by Segment) ,2016-2018
Figure 10.57:    Koninklijke Philips N.V.: Revenue (by Region), 2016-2018
Figure 10.58:    Koninklijke Philips N.V.: R&D Expenditure, 2016-2018
Figure 10.59:    Koninklije Philips N.V.: SWOT Analysis
Figure 10.60:    Medopad Ltd: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.61:    Medopad Ltd: SWOT Analysis
Figure 10.62:    Mindstrong Health: Product Portfolio for the Global Digital Biomarkers Market
Figure 9.63:    Mindstrong Health: SWOT Analysis
Figure 10.64:    Neurotrack Technologies, Inc: Product Portfolio for Global Digital Biomarkers Market
Figure 10.65:    Neurotrack Technologies, Inc: SWOT Analysis
Figure 10.66:    Novartis International AG: Overall Financials, 2016-2018
Figure 10.67:    Novartis AG: Revenue (by Segment), 2016-2018
Figure 10.68:    Novartis AG: Revenue (by Region), 2016-2018
Figure 10.69:    Novartis International AG, R&D Expenditure, 2016-2018
Figure 10.70:    Novartis International AG: SWOT Analysis
Figure 10.71:    Orikami: SWOT Analysis
Figure 10.72:    Pfizer, Inc: Overall Financials, 2016-2018
Figure 10.73:    Pfizer Inc: Revenue (by Segment), 2016-2018
Figure 10.74:    Pfizer Inc: Revenue (by Region), 2016-2018
Figure 10.75:    Pfizer Inc.: R&D Expenditure, 2016-2018
Figure 10.76:    Pfizer Inc.: SWOT Analysis
Figure 10.77:    Quanterix Corporation: Product Portfolio for Global Digital Biomarkers Market
Figure 10.78:    Quanterix Corporation: Overall Financials, 2015-2017
Figure 10.79:    Quanterix Corporation: Revenue (by Region), 2015-2017
Figure 10.80:    Quanterix Corporation: R&D Expenditure, 2015-2017
Figure 10.81:    Quanterix Corporation: SWOT Analysis
Figure 10.82:    Sanofi S.A.: Overall Financials, 2016-2018
Figure 10.83:    Sanofi: S.A. Revenue (by Business Segments), 2016-2018
Figure 10.84:    Sanofi S.A.: Revenue (by Region), 2016-2018
Figure 10.85:    Sanofi S.A.: R&D Expenditure 2016-2018
Figure 10.86:    Sanofi S.A.: SWOT Analysis
Figure 10.87:    The Takeda Pharmaceuticals Company Limited: Overall Financials, 2016-2018
Figure 10.88:    The Takeda Pharmaceuticals Company Limited: Revenue (by Region), 2016-2018
Figure 10.89:    The Takeda Pharmaceuticals Company Limited: R&D Expenditure, 2016-2018
Figure 10.90:    The Takeda Pharmaceuticals Company Limited: SWOT Analysis
Figure 10.91:    Verily Life Sciences: SWOT Analysis
Figure 10.92:    Cambridge Cognition Plc: Product Portfolio for the Global Digital Biomarkers Market
Figure 10.93:    MC10 Inc: Product Portfolio for Global Digital Biomarkers Market

You may also like

Published Year: 2018

Global Big Data in Healthcare Market: Analysis and Forecast, 2017-2025 (Focus on Components and Services, Applications, Competitive Landscape and Country Analysis)

The global big data in healthcare market was estimated to be worth $14.25 billion in 2017, and...

 
Published Year: 2018

Global Mobile Medical Apps Market: Focus on Category, Type, Application, Countries, Patents, Market Share, and Competitive Landscape - Analysis and Forecast (2017-2025)

The global mobile medical apps market was estimated at $1.40 billion in 2016, and is...

 
Published Year: 2017

Global Medical Image Analytics Market : Analysis and Forecast (2017-2025) (Focus on Products, Applications, Imaging Modalities, End Users, Country Analysis, Patent Analysis, Market Share Analysis, and Competitive Landscape)

Medical image analysis software application perform a vital role after the image has been...

 
Published Year: 2017

Global High Acuity Information Solutions Market (2017-2025) (Focus on Product, End User, and Competitive Landscape)

The global high acuity information solutions market is expected to reach $13.69 billion by the...

 
Published Year: 2017

Global Population Health Management Solutions Market : Analysis and Forecast (2017-2025) (Focus on Products (Software & Services), Country Analysis, End Users, Competitive Landscape, Market Share Analysis, and Region Specific Information)

The global population health management solution market can be segmented on the basis of type...

 
Published Year: 2020

Analyst Note:Implications of COVID-19 on Digital Health

The digital health space has significantly exploded particularly in the last decade. More than...

Global Digital Biomarkers Market

Focus on Key Trends, Growth Potential, Competitive Landscape, Components (Data Collection and Integration), End Users, Application (Sleep and Movement, Neuro, Respiratory and Cardiological Disorders) and Region – Analysis and Forecast, 2019-2025